Document is current
Any future updates will be listed below
-
Authors
Holtze, Colin H. https://orcid.org/0000-0003-1069-9874
Freiheit, Elizabeth A.
Limb, Susan L.
Stauffer, John L.
Raimundo, Karina
Pan, Wayne T.
Flaherty, Kevin R.
Kim, Hyun J.
-
Funding
Funding for this research was provided by:
Pulmonary Fibrosis Foundation (n/a)
- License Information
-
More Information
Article History
Received: 18 November 2019
Accepted: 4 February 2020
First Online: 10 February 2020
Ethics approval and consent to participate
: The PFF-PR study was reviewed and approved by the institutional review boards at each registry site, and patient participants signed informed consent.
: Not applicable.
: CH is supported by NIH Grant No. T32 HL007749–26. EF is a managing director of the SABER unit within the department of biostatistics at the University of Michigan. SABER receives funding from the Pulmonary Fibrosis Foundation. JS, SL and KR are employees of Genentech. WP is a former employee of Genentech. He is currently employed at BioMarin. KF reports personal fees from Veracyte and Sanofi Genzyme; and grants and personal fees from Roche/Genentech and Boehringer Ingelheim, outside of the submitted work. HK has served as site principle investigator for IPF clinical trials sponsored by InterMune, Gilead, Sanofi, Celgene, and Centocor.
